- 作者：Antonio Ponce-Vargas
- 关键词：Artrosis ; Sulfato de glucosamina ; Fá ; rmacos modificadores de la enfermedad para la artrosis
- 刊名：Seminarios de la Fundaci贸n Espa帽ola de Reumatolog铆a
- 出版年：2006
- 期刊代码：pca343_15773566
- 类别：med
- 出版时间：March 2006
- 卷：7
- 期：1
- 页码：3-11
- 文件大小：157 K
Osteoarthritis (OA) is one of the most frequent causes of pain and disability in the elderly. Given the old population's increase, therapeutic interventions are necessary to allow retarding the deleterious effects on the health of people. Consequently, a responsible sanitary policy should keep in mind this social demand and a high-priority focus of resources for this prevalent disease. There is now a renewed clinical and research interest in this complaint. Greather physiopathological understanding of the immunological and enzymatic changes that influence the disease have modified the mechanical concept once held of its pathogenicity to include other more dynamic and biological causes in which plays a basic role. Furthermore, it would also be sensitive to pharmacological treatment, thus delaying the degenerative process. Glucosamine sulphate (GS) is a molecule with a wide range of biological actions with some of the most important being the antiinflammatory effect and an increased metabolism of the cartilage matrix. Recent studies in vitro show a profile of chondro-modulation that favors the anabolism of the chondrocyte. Similarly, long-term, prospective, placebo-controlled studies have shown an improvement in the symptoms and of the progression of the narrowing of the articular space in people treated with GS, with a profile of similar safety to the placebo groups. The following article carries out an approach to the control of the illness with the Delayed-acting symptomatic drugs and disease modyfing drugs in the OA and it reviews the available evidences of GS in the specific treatment of OA.